Targeting p53 pathways: mechanisms, structures, and advances in therapy

H Wang, M Guo, H Wei, Y Chen - Signal transduction and targeted …, 2023 - nature.com
The TP53 tumor suppressor is the most frequently altered gene in human cancers, and has
been a major focus of oncology research. The p53 protein is a transcription factor that can …

Proteostasis of islet amyloid polypeptide: a molecular perspective of risk factors and protective strategies for type II diabetes

D Milardi, E Gazit, SE Radford, Y Xu… - Chemical …, 2021 - ACS Publications
The possible link between hIAPP accumulation and β-cell death in diabetic patients has
inspired numerous studies focusing on amyloid structures and aggregation pathways of this …

Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function

L Palanikumar, L Karpauskaite, M Al-Sayegh… - Nature …, 2021 - nature.com
Missense mutations in p53 are severely deleterious and occur in over 50% of all human
cancers. The majority of these mutations are located in the inherently unstable DNA-binding …

p53 amyloid aggregation in cancer: function, mechanism, and therapy

J Li, M Guo, L Chen, Z Chen, Y Fu, Y Chen - Experimental Hematology & …, 2022 - Springer
Similar to neurodegenerative diseases, the concept that tumors are prion like diseases has
been proposed in recent years. p53, the most well-known tumor suppressor, has been …

Therapeutic potential of foldamers: from chemical biology tools to drug candidates?

R Gopalakrishnan, AI Frolov, L Knerr… - Journal of Medicinal …, 2016 - ACS Publications
Over the past decade, foldamers have progressively emerged as useful architectures to
mimic secondary structures of proteins. Peptidic foldamers, consisting of various amino acid …

The β-cell assassin: IAPP cytotoxicity

D Raleigh, X Zhang, B Hastoy… - Journal of molecular …, 2017 - jme.bioscientifica.com
Islet amyloid polypeptide (IAPP) forms cytotoxic oligomers and amyloid fibrils in islets in type
2 diabetes (T2DM). The causal factors for amyloid formation are largely unknown …

Allosteric activation dictates PRC2 activity independent of its recruitment to chromatin

CH Lee, JR Yu, S Kumar, Y Jin, G LeRoy, N Bhanu… - Molecular cell, 2018 - cell.com
PRC2 is a therapeutic target for several types of cancers currently undergoing clinical trials.
Its activity is regulated by a positive feedback loop whereby its terminal enzymatic product …

Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics

CS Swenson, G Mandava, DM Thomas… - Chemical …, 2024 - ACS Publications
The development of potent, specific, and pharmacologically viable chemical probes and
therapeutics is a central focus of chemical biology and therapeutic development. However, a …

[HTML][HTML] An investigation into the potential action of polyphenols against human Islet Amyloid Polypeptide aggregation in type 2 diabetes

A Mahboob, DKL Senevirathne, P Paul, F Nabi… - International Journal of …, 2023 - Elsevier
Abstract Type 2 diabetes (T2D), a chronic metabolic disease characterized by
hyperglycemia, results in significant disease burden and financial costs globally. Whilst the …

p53 and zinc: a malleable relationship

JH Ha, O Prela, DR Carpizo, SN Loh - Frontiers in Molecular …, 2022 - frontiersin.org
A large percentage of transcription factors require zinc to bind DNA. In this review, we
discuss what makes p53 unique among zinc-dependent transcription factors. The …